Mar 19 2015
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced the online availability of three abstracts that will be presented during the April 18-22 American Association of Cancer Research (AACR) Annual Meeting in Philadelphia.
The abstracts were published online at www.aacr.org.
"We are very pleased with the high quality of our data being presented at AACR and believe these data further validate the ability of our Accurins to control the biodistribution of therapeutic payloads and target diseased cells while minimizing on target but off tissue toxicities, thereby creating the potential for best-in-class therapeutics," said Andrew Hirsch, president and chief executive officer of BIND. "The posters also reflect our commitment to creating innovative collaborations with leading biopharmaceutical companies to augment our internal pipeline and fully leverage our proprietary nanomedicine platform."
The posters will include preclinical and clinical pharmacokinetic data from BIND’s lead Accurin compound, BIND-014, and preclinical data from BIND’s collaboration with AstraZeneca on the Aurora B kinase inhibitor Accurin-AZD1152HQPA (AZD2811).
Poster presentations at AACR include the following:
BIND-014
- Poster title: Pharmacokinetic of BIND-014 (docetaxel nanoparticles for injectable suspension) in preclinical species and patients with advanced solid tumors (Abstract #5514, Poster board #2)
- Date/time: April 22, 2015; 8 am – 12 pm EDT
- Poster session category: Chemistry
- Location: Poster section 36
Accurin AZD1152HQPA (AZD2811)
- Collaborator: AstraZeneca
- Poster Title: AZD1152HQPA Accurin nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer (Abstract #3102, Poster board #15)
- Date/time: April 21, 2015; 8 am – 12 pm EDT
- Poster session category: Molecular and Cellular Biology
- Location: Poster section 9
- Poster Title: Imaging AZD1152HQPA Accurin nanoparticle accumulation in preclinical tumors (Abstract #3678, Poster board #11)
- Date/time: April 21, 2015; 8 am – 12 pm EDT
- Poster session category: Chemistry
- Location: Poster section 35
Source: http://bindtherapeutics.com/